ClinicalTrials.gg
RecruitingNCT07189260Updated Sep 23, 2025

Pre- and Postoperative Chest Therapy With Positive Expiratory Pressure (PEP) to Prevent Hospital-acquired Pneumonia

An interventional study of positive expiratory pressure in Hip Fractures (ICD-10 72.01-72.2), sponsored by University Hospital Bispebjerg and Frederiksberg. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by University Hospital Bispebjerg and Frederiksberg · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2024, registered Jun 2025).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
566
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Hip Fractures with a site in Denmark — 8 open to participants now, 10 under way, none of them phase 3. Hip Fractures · Denmark.

Planned enrollment
5th of 45
566 · median 90
Started
2024
with 3 others
No phase
22 of 57
5 open now
Registered
55th of 57
by date
Lead sponsor
2 of 57
University Hospital Bispebjerg and Frederiksberg

Among the 57 studies in Hip Fractures with a site in Denmark, this one is the 5th largest by planned enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2024, is one of 22 with no phase, and was the 55th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

8 of the 57 studies in Hip Fractures with a site in Denmark are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hip Fractures with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate whether pre- and postoperative treatment with systematic PEP therapy can prevent hospital-acquired pneumonia in patients with hip frac-ture. It will also learn about the barriers regarding PEP therapy in this group of patients.

  • Does pre- and postoperative treatment with systematic PEP therapy prevent hospital-acquired pneumonia in patients with hip fracture?
  • Which barriers do participants have regarding PEP therapy in this group of patients? Researchers will compare systematic PEP therapy to no intervention besides standard treat-ment to see if systematic therapy with PEP can prevent hospital-acquired pneumonia.

Participants will:

  • Receive systematic PEP therapy during hospitalization or no intervention besides standard treatment
  • Register the PEP therapy four times daily on a paper checklist. Failure to perform the treatment and the reason must also be documented on the checklist.
03

Conditions studied

  • Hip Fractures (ICD-10 72.01-72.2)

Keywords

  • hip fracture
  • pneumonia
  • PEP therapy
  • positive expiratory pressure
  • RCT
  • hospital-acquired pneumonia
  • systematic treatment with PEP
  • osteoporosis
  • frailty
  • multimorbidity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hip fracture regardless of age
  • Cognitively well-functioning
  • Able to understand the study and give
  • Able to speak and understand Danish
  • Resident of Region Hovedstaden or Region Sjælland

Exclusion criteria

Exclusion Criteria:

  • Cognitively impaired
  • Unable to understand the study and give
  • Pneumonia upon admission
  • Delirium upon admission
  • Pneumothorax

For patients with e.g. dementia or brain injury, the ability to give informed consent will be assessed individually.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
566 participants (estimated)

Study arms

  • Active comparator
    Active

    Medical therapy device

    Device: positive expiratory pressure

  • No intervention
    Standard treatment

    Standard treatment

Interventions

  • Devicepositive expiratory pressure

    PEP therapy

06

What researchers measure

Primary outcomes

  1. The incidence of hospital-acquired pneumonia

    Primary Outcome is the incidence of hospital-acquired pneumonia in the control and intervention group. Documented in the Sundhedsplatformen and diagnosed with one ore more of the following: * Thoracic x-ray * Sputum culture * Auscultation * Infection markers

    Time frame: During hospitalization, from intervention start to discharge, which is on average one week

Secondary outcomes

  1. Number of participants dead within 30-days after discharge

    Number of participants dead within 30 days after discharge

    Time frame: 30-day mortality, assessed 30 days after discharge from the orthopedic ward

  2. Number of participants readmitted within 30-days after discharge

    Number of participants readmitted within 30 days after discharge

    Time frame: 30-day readmission post-discharge, assessed 30 days after discharge from the orthopedic ward

  3. Incidence of delirium during hospitalization (journal entry, CAM-screening, diagnosis), up to 4 weeks.

    Incidence of delirium during hospitalization (journal entry, CAM-screening, diagnosis), up to 4 weeks.

    Time frame: During hospitalization, from intervention start to discharge, which is on average one week

  4. Degree of regained basic mobility (Cumulated Ambulation Score - CAS) on the the day of discharge compared to the assement made at admission.

    Degree of regained basic mobility (Cumulated Ambulation Score - CAS) on the the day of discharge compared to the assement made at admission. CAS values ranges from 0 to 6. A score of 6 represents an independant patient in regards to getting in and out of bed, sit-to-stand from a chair, and walking. A score of 0 represents a patient completely dependant on help getting in and out of bed, sit-to-stand from a chair, and walking.

    Time frame: CAS the weeks up to hip fracture and CAS at discharge, which is on average one week after admission

  5. Discharge destination (home, nursing home, care facility, rehab, another ward/hospital, etc.). Number of participants discharged to home, care facility, rehab, another hospital/ward or ot he discharge destination.

    Discharge destination (home, nursing home, care facility, rehab, another ward/hospital, etc.). Number of participants discharged to home, care facility, rehab, another hospital/ward or o the discharge destination.

    Time frame: Assessed at discharge from the orthopedic department, which is on average one week efter admission

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), will be provided to anyone who wishes to access the data.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2029, 70 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 70 months is above that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Sep 23, 2025
StartActual
Feb 19, 2024
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07189260
Lead sponsor
University Hospital Bispebjerg and Frederiksberg
Responsible party
Charlotte Densing (Project nurse, University Hospital Bispebjerg and Frederiksberg) — Principal investigator
First posted
Sep 23, 2025
Start date
Feb 19, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion